BB-94 acid | 130370-82-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: BB-94 acid
• 英文别名: (2S,3R)-5-Methyl-3-((S)-1-methylcarbamoyl-2-phenyl-ethylcarbamoyl)-2-(thiophen-2-ylsulfanylmethyl)-hexanoic acid；(2S,3R)-5-methyl-3-[[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]-2-(thiophen-2-ylsulfanylmethyl)hexanoic acid
• CAS: 130370-82-0
• 化学式: C₂₃H₃₀N₂O₄S₂
• 分子量: 462.634
• InChiKey: DDIMOHDQZATCIL-QYZOEREBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  31
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  149
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  BB-94 acid 生成 巴马司他
  参考文献：
  名称：

  Hydroxamino acid based collagenase inhibitors

  摘要：

  通式I的化合物：##STR1## 其中：R.sup.1代表C.sub.1-C.sub.6烷基，苯基，噻吩基，取代苯基，苯基（C.sub.1-C.sub.6）烷基，杂环基，（C.sub.1-C.sub.6）烷基羰基苯乙基或取代苯基羰基苯乙基；或者，当n=O时，R.sup.1代表SR.sup.x，其中R.sup.x代表一个基团：##STR2## R.sup.2代表氢原子或C.sub.1-C.sub.6烷基，C.sub.1-C.sub.6烯基，苯基（C.sub.1-C.sub.6）烷基，环烷基（C.sub.1-C.sub.6）烷基或环烯基（C.sub.1-C.sub.6）烷基；R.sup.3代表具有R或S立体化学的氨基酸残基或C.sub.1-C.sub.6烷基，苄基，（C.sub.1-C.sub.6烷氧基）苄基或苄氧（C.sub.1-C.sub.6烷基）基；R.sup.4代表氢原子或C.sub.1-C.sub.6烷基；R.sup.5代表氢原子或甲基；n是一个整数，其值为0、1或2；A代表C.sub.1-C.sub.6碳氢链，可选地取代一个或多个C.sub.1-C.sub.6烷基，苯基或取代苯基基团；其盐和N-氧化物是胶原酶抑制剂，可用于治疗涉及组织降解和/或促进伤口愈合的疾病。涉及组织降解的疾病包括关节病（特别是类风湿性关节炎），炎症，皮肤病，骨吸收疾病和肿瘤侵袭。

  公开号：

  US05310763A1
• 作为产物：
  描述：

  (2R)-2-[1-(tert-butoxycarbonyl)vinyl]-4-methylpentanoic acid 在 乙胺嗪 、 丹酰尸胺 、 1-羟基苯并三唑 、 三乙胺 、 三氟乙酸 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 BB-94 acid
  参考文献：
  名称：

  Selective inhibition of low affinity IgE receptor (CD23) processing

  摘要：

  A series of hydroxamic acids related to the non-selective matrix metalloproteinase inhibitor Batimastat has been prepared, some members of which are potent inhibitors of the processing of the low affinity IgE receptor (CD 23). Increased activity is obtained by appropriate substitution at the a-position, whilst selectivity is gained by use of a P1' benzyl group in conjunction with a C-terminal primary amide. (C) 1997 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(97)10149-4

文献信息

• Hydroxamino acid based collagenase inhibitors
  申请人：British Bio-technology Limited

  公开号：US05310763A1

  公开（公告）日：1994-05-10

  Compounds of general formula I: ##STR1## wherein: R.sup.1 represents a C.sub.1 -C.sub.6 alkyl, phenyl, thiophenyl, substituted phenyl, phenyl(C.sub.1 -C.sub.6)alkyl, heterocyclyl, (C.sub.1 -C.sub.6)alkylcarbonyl phenacyl or substituted phenacyl group; or, when n=O, R.sup.1 represents SR.sup.x, wherein R.sup.x represents a group: ##STR2## R.sup.2 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkenyl, phenyl(C.sub.1 -C.sub.6)alkyl, cycloalkyl(C.sub.1 -C.sub.6)alkyl or cycloalkenyl(C.sub.1 -C.sub.6)alkyl group; R.sup.3 represents an amino acid residue with R or S stereochemistry or a C.sub.1 -C.sub.6 alkyl, benzyl, (C.sub.1 -C.sub.6 alkoxy)benzyl or benzyloxy(C.sub.1 -C.sub.6 alkyl) group; R.sup.4 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group; R.sup.5 represents a hydrogen atom or a methyl group; n is an integer having the value 0, 1 or 2; and A represents a C.sub.1 -C.sub.6 hydrocarbon chain, optionaly substituted with one or more C.sub.1 -C.sub.6 alkyl, phenyl or substituted phenyl groups; and their salts and N-oxides are collagenase inhibitors are and useful in the management of disease involving tissue degradation and/or the promotion of wound healing. Diseases involving tissue degradation include arthropathy (particularly rheumatoid arthritis), inflammation, dermatological diseases, bone resorption diseases and tumor invasion.

  通式I的化合物：##STR1## 其中：R.sup.1代表C.sub.1-C.sub.6烷基，苯基，噻吩基，取代苯基，苯基（C.sub.1-C.sub.6）烷基，杂环基，（C.sub.1-C.sub.6）烷基羰基苯乙基或取代苯基羰基苯乙基；或者，当n=O时，R.sup.1代表SR.sup.x，其中R.sup.x代表一个基团：##STR2## R.sup.2代表氢原子或C.sub.1-C.sub.6烷基，C.sub.1-C.sub.6烯基，苯基（C.sub.1-C.sub.6）烷基，环烷基（C.sub.1-C.sub.6）烷基或环烯基（C.sub.1-C.sub.6）烷基；R.sup.3代表具有R或S立体化学的氨基酸残基或C.sub.1-C.sub.6烷基，苄基，（C.sub.1-C.sub.6烷氧基）苄基或苄氧（C.sub.1-C.sub.6烷基）基；R.sup.4代表氢原子或C.sub.1-C.sub.6烷基；R.sup.5代表氢原子或甲基；n是一个整数，其值为0、1或2；A代表C.sub.1-C.sub.6碳氢链，可选地取代一个或多个C.sub.1-C.sub.6烷基，苯基或取代苯基基团；其盐和N-氧化物是胶原酶抑制剂，可用于治疗涉及组织降解和/或促进伤口愈合的疾病。涉及组织降解的疾病包括关节病（特别是类风湿性关节炎），炎症，皮肤病，骨吸收疾病和肿瘤侵袭。
• Selective inhibition of low affinity IgE receptor (CD23) processing
  作者：Stuart Bailey、Brian Bolognese、Derek R Buckle、Andrew Faller、Sally Jackson、Pearl Louis-Flamberg、Mark McCord、Ruth J Mayer、Lisa A Marshall、David G Smith

  DOI：10.1016/s0960-894x(97)10149-4

  日期：1998.1

  A series of hydroxamic acids related to the non-selective matrix metalloproteinase inhibitor Batimastat has been prepared, some members of which are potent inhibitors of the processing of the low affinity IgE receptor (CD 23). Increased activity is obtained by appropriate substitution at the a-position, whilst selectivity is gained by use of a P1' benzyl group in conjunction with a C-terminal primary amide. (C) 1997 Elsevier Science Ltd. All rights reserved.